Talazoparib
Talzenna (talazoparib) is a small molecule pharmaceutical. Talazoparib was first approved as Talzenna on 2018-10-16. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against poly [ADP-ribose] polymerase 2 and poly [ADP-ribose] polymerase 1. Talzenna's patents are valid until 2031-10-20 (FDA).
| Trade Name | Talzenna |
|---|---|
| Common Name | Talazoparib |
| Indication | breast neoplasms |
| Drug Class | Poly-ADP-ribose polymerase inhibitors |
